Connect Sign In
The U.S. District Court for the Eastern District of Texas today struck down the FDA’s final rule to regulate laboratory-developed tests. |
March 31, 2025 | ARUP Applauds Federal Court Decision Vacating the FDA’s Final Rule Regulating Lab-Developed Tests The rule and its compliance deadlines are no longer in effect, benefiting patient care, innovation, and the greater laboratory community, ARUP leaders said. |
|
March 11, 2025 | Pramana and ARUP Laboratories Partner To Digitize Pathology Slides and Develop AI-Powered Hematopathology Algorithms for Deployment via Edge AI Pramana, Inc., and ARUP are collaborating to improve the assessment of bone marrow biopsies and address other key diagnostic challenges in hematopathology. |
The robotic arm removes the wet-mount specimen slide in preparation for scanning. Once scanned, the image will be screened via artificial intelligence (AI) for evidence of ova and parasites. |
March 6, 2025 | ARUP Laboratories Expands AI-Augmented Parasitology Screening Tool, Improves Detection and Diagnosis ARUP will expand its AI-augmented screening tool for the detection of human gastrointestinal parasites to become first and only lab to apply AI to the entire ova and parasite testing process. |
The partnership combines Tasso’s clinical grade blood collection solutions, such as the Tasso+ device pictured above, with ARUP’s gold standard testing capabilities to streamline and accelerate decentralized clinical research. |
February 3, 2025 | Tasso and ARUP Laboratories Announce Partnership, Combined Offering for Decentralized Clinical Research Biomarker Testing The partnership combines Tasso’s clinical grade blood collection solutions and ARUP’s gold standard testing capabilities to streamline and accelerate decentralized clinical research. |
ARUP’s new assay, Influenza A (H5) Virus by Qualitative NAAT (ARUP test number 3018970), will expand the national capacity to detect the current outbreak of highly pathogenic avian influenza A (H5N1). |
January 3, 2025 | ARUP Offers New Assay To Detect Influenza A (H5) Virus ARUP has launched a new assay for the detection and subtyping of influenza A (H5) virus, which will expand the national capacity to detect the current outbreak of highly pathogenic avian influenza A (H5N1). |
ARUP Laboratories and Augurex Life Sciences Corp. are partnering to incorporate a 14-3-3η test that will aid in the early detection and management of rheumatoid arthritis. |
October 21, 2024 | Augurex Announces Agreement With ARUP To Expand Access to Advanced Rheumatoid Arthritis Diagnosis ARUP Laboratories is partnering with Augurex Life Sciences Corp. to include the 14-3-3η test in the ARUP test menu to enhance the early detection of rheumatoid arthritis. |
ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ We accelerate the development and adoption of cutting-edge diagnostic and prognostic technologies advancing patient care through groundbreaking science and engineering. The Sherrie Perkins Research and Innovation Collaboration Grant The Sherrie Perkins Research and Innovation Collaboration Grant funds cutting-edge research in laboratory medicine.
Press Releases
Live Chat